Please use this identifier to cite or link to this item:
|Title:||Gemcitabine and platinum pathway pharmacogenetics in Asian breast cancer patients||Authors:||Wong, A.L.-A.
|Issue Date:||Sep-2011||Citation:||Wong, A.L.-A.,Yap, H.-L.,Yeo, W.-L.,Soong, R.,Ng, S.-S.,Wang, L.-Z.,Cordero, M.T.,Yong, W.-P.,Goh, B.-C.,Lee, S.-C. (2011-09). Gemcitabine and platinum pathway pharmacogenetics in Asian breast cancer patients. Cancer Genomics and Proteomics 8 (5) : 255-259. ScholarBank@NUS Repository.||Abstract:||Background/Aim: Gemcitabine/carboplatin is efficacious in breast cancer but results in significant hematologic toxicities. We employed a multi-gene approach to identify variants to predict its toxicities. Patients and Methods: Twenty-six gemcitabine and platinum-based DNA repair pathway polymorphisms were correlated with gemcitabine pharmacokinetics, hematologic toxicities, response and survival in 41 Asian breast cancer patients receiving gemcitabine/ carboplatin. Results: The combined effects of solute carrier family (SLC)28A1+1528C>T and thymidylate synthetase (TYMS)+1494del6 significantly influenced hematologic toxicities: 89% of patients who possessed either SLC28A1+1528TT or TYMS+1494ins6/ins6 (n=9) developed grade 4 thrombocytopenia, versus 14% with neither genotype (n=29; p||Source Title:||Cancer Genomics and Proteomics||URI:||http://scholarbank.nus.edu.sg/handle/10635/110740||ISSN:||11096535|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Sep 6, 2019
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.